ABCL
AbCellera Biologics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
AbCellera Biologics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 24 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
AbCellera Biologics Inc.
12.27
+0.09 · +0.70%
post 12.16 −0.86%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for AbCellera Biologics Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for AbCellera Biologics Inc..
—
Tall tick = annual report · Source: EDGAR
Linked news
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $259.1M | 27.01% | +9.04% |
| Capital World Investors | $106.7M | 11.12% | +1.70% |
| Two Sigma | $81.9M | 8.54% | −1.18% |
| TD Waterhouse Canada | $72.6M | 7.57% | +0.04% |
| Bank of America | $48.2M | 5.02% | +104.72% |
| Manager | Value | % base | |
|---|---|---|---|
| Baker Bros. | $259.1M | 27.01% | +9.04% |
| Capital World Investors | $106.7M | 11.12% | +1.70% |
| Two Sigma | $81.9M | 8.54% | −1.18% |
| TD Waterhouse Canada | $72.6M | 7.57% | +0.04% |
| Bank of America | $48.2M | 5.02% | +104.72% |
Expected move
Inputsstraddle ±18.5%
spot 12.28exp Nov 20ATM strike 12ATM straddle 2.68IV 133%